<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547585</url>
  </required_header>
  <id_info>
    <org_study_id>SOY-CVD-2012</org_study_id>
    <secondary_id>RBPI#1746</secondary_id>
    <nct_id>NCT01547585</nct_id>
  </id_info>
  <brief_title>A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy</brief_title>
  <acronym>SOY-LDL</acronym>
  <official_title>A Randomized Controlled Trial to Determine the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Whole Soy: a Dose Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guelph Food Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Guelph</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glycemic Index Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Centre for Agri-Food Research in Health and Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guelph Food Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to test the hypothesis that daily consumption of a baked food
      product containing whole soy for 6 weeks will significantly reduce plasma Low Density
      Lipoprotein Cholesterol (LDL-C) in individuals with hypercholesterolemia. As such the overall
      goals of this study are to determine whether daily consumption of muffins made from whole soy
      flour for 6 weeks can lower plasma LDL-Cholesterol, and if so, establish whether the effect
      is dose-dependent. To do this, study collaborators will: (1) conduct a detailed chemical and
      physical characterization of certified defatted whole soy flour that will be incorporated
      into a muffin; (2) formulate and produce a palatable whole soy flour muffin along with a
      control muffin containing wheat flour; (3) conduct a parallel controlled trial in which soy
      muffins will be fed randomly to persons with elevated LDL-cholesterol in a human clinical
      trial. All participants will be randomized into one of three groups and asked to eat two
      muffins daily for 6 weeks in the following combination: high dose soy; control group or low
      dose soy. Before, after, and mid-way during the feeding period, blood samples will be
      obtained for measurements of lipids, glucose, insulin, inflammation, and soy phytochemicals.
      The effect of soy consumption on waist circumference, body mass index (BMI) and blood
      pressure will also be examined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDL-Cholesterol)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>high sensitivity c-reactive protein (hsCRP)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>CRP</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>- Isocaloric control muffins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Soy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Isocaloric muffins containing low dose of soy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Soy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Isocaloric muffins containing high dose soy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized soy containing muffin</intervention_name>
    <description>Standardized muffin containing two levels of soy</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Low Dose Soy</arm_group_label>
    <arm_group_label>High Dose Soy</arm_group_label>
    <other_name>Soy containing muffins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females (not pregnant or lactating) aged 30-70 year

          -  Body mass index (BMI) ≤40kg/m² and ≥18.5kg/m²

          -  Fasting plasma total cholesterol ≥5.0

          -  Fasting plasma LDL cholesterol ≥3.0 and &lt;5.0 mmol/L.

        Exclusion Criteria:

          -  Fasting plasma triglycerides ≥4.0 mmol/L

          -  Abnormal liver and kidney function

          -  Unstable body weight(&gt;3kg change in 3 months) or intention to lose or gain weight;

          -  Diabetes mellitus (fasting plasma glucose ≥7.0 mmol/L or use of insulin or any
             hypoglycemic or anti-hyperglycemic medication);

          -  Use of any prescription or non-prescription drug, prebiotics or probiotics, herbal or
             nutritional supplement known to affect blood lipids, except for stable doses (no
             change in 3 months) of thyroxine, oral contraceptive agents, hormone replacement
             therapy, and medications for controlling blood pressure);

          -  Major surgical or medical events within the past 3 months;

          -  Presence of a gastrointestinal disorder or medication that alters the digestion and
             absorption of nutrients; including antibiotic use within the past 6 weeks.

          -  Consumption of a diet containing ≥15% of energy from saturated fat;

          -  Any food allergy or aversion or unwillingness to eat wheat, soy or milk;

          -  Consumption of ≥5 servings per week of soy based food products;

          -  Consumption of an average of &gt;2 alcoholic beverages per day;

          -  Regular smokers (smoking ≥1 cigarette per day) of cigarettes or cigars
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Duncan, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guelph</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Wolever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glycemic Index Laboratories, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heather Blewett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Centre for Agri-Food Research in Health and Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canadian Centre for Agri-food Research in Health and Medicine</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Human Nutraceutical Research Unit. University of Guelph</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1G 2W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycemic Index Laboratories, Inc</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Reinwald S, Akabas SR, Weaver CM. Whole versus the piecemeal approach to evaluating soy. J Nutr. 2010 Dec;140(12):2335S-2343S. doi: 10.3945/jn.110.124925. Epub 2010 Oct 27. Review.</citation>
    <PMID>20980652</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Shu XO, Gao YT, Yang G, Li Q, Li H, Jin F, Zheng W. Soy food consumption is associated with lower risk of coronary heart disease in Chinese women. J Nutr. 2003 Sep;133(9):2874-8.</citation>
    <PMID>12949380</PMID>
  </reference>
  <reference>
    <citation>Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S; JPHC Study Group. Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. Circulation. 2007 Nov 27;116(22):2553-62. Epub 2007 Nov 19.</citation>
    <PMID>18025534</PMID>
  </reference>
  <reference>
    <citation>Nanri A, Mizoue T, Takahashi Y, Kirii K, Inoue M, Noda M, Tsugane S. Soy product and isoflavone intakes are associated with a lower risk of type 2 diabetes in overweight Japanese women. J Nutr. 2010 Mar;140(3):580-6. doi: 10.3945/jn.109.116020. Epub 2010 Jan 6.</citation>
    <PMID>20053935</PMID>
  </reference>
  <reference>
    <citation>Yang B, Chen Y, Xu T, Yu Y, Huang T, Hu X, Li D. Systematic review and meta-analysis of soy products consumption in patients with type 2 diabetes mellitus. Asia Pac J Clin Nutr. 2011;20(4):593-602.</citation>
    <PMID>22094845</PMID>
  </reference>
  <reference>
    <citation>Anderson JW, Bush HM. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr. 2011 Apr;30(2):79-91. Review.</citation>
    <PMID>21730216</PMID>
  </reference>
  <reference>
    <citation>Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995 Aug 3;333(5):276-82.</citation>
    <PMID>7596371</PMID>
  </reference>
  <reference>
    <citation>Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. 2005 Feb;81(2):397-408.</citation>
    <PMID>15699227</PMID>
  </reference>
  <reference>
    <citation>Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab. 2006 Mar;91(3):772-80. Epub 2005 Dec 29. Review.</citation>
    <PMID>16384855</PMID>
  </reference>
  <reference>
    <citation>Sirtori CR, Eberini I, Arnoldi A. Hypocholesterolaemic effects of soya proteins: results of recent studies are predictable from the anderson meta-analysis data. Br J Nutr. 2007 May;97(5):816-22. Review.</citation>
    <PMID>17408521</PMID>
  </reference>
  <reference>
    <citation>Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M; American Heart Association Nutrition Committee. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006 Feb 21;113(7):1034-44. Epub 2006 Jan 17.</citation>
    <PMID>16418439</PMID>
  </reference>
  <reference>
    <citation>Klein MA, Nahin RL, Messina MJ, Rader JI, Thompson LU, Badger TM, Dwyer JT, Kim YS, Pontzer CH, Starke-Reed PE, Weaver CM. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr. 2010 Jun;140(6):1192S-1204S. doi: 10.3945/jn.110.121830. Epub 2010 Apr 14.</citation>
    <PMID>20392880</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guelph Food Research Centre</investigator_affiliation>
    <investigator_full_name>Dan Ramdath</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Soy</keyword>
  <keyword>Dose-response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 28, 2017</submitted>
    <returned>April 12, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

